Nektar Therapeutics (NKTR)

33.40
NASDAQ : Health Technology
Prev Close 34.03
Day Low/High 33.23 / 34.24
52 Wk Low/High 29.22 / 69.76
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 5.93B
EPS 4.00
P/E Ratio 8.64
Div & Yield N.A. (N.A)
GE and Kohl's Are Among 2 Stocks Poised For Reversal

GE and Kohl's Are Among 2 Stocks Poised For Reversal

These names are showing bullish and bearish technical patterns over the past week.

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Stocks finished higher on Wednesday.

Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

It is premature to think that this market has hit a top until there is further evidence in the price action.

Next Week Could Be Confusing

Many summer winners are in correction mode.

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Huge profits could be on the doorstep for these hot breakout setups.

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

The Oracle of Omaha believes in the future of U.S. business, says Jim Cramer. Plus, Buffett can admit his mistakes and we can learn from that.

First Week of June 16th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Traders Are Aggressively Fading the Open

Traders Are Aggressively Fading the Open

But what will be most important is whether support stays strong and the buyers show interest in the afternoon.

Rev's Forum: Don't Just Sit There, Do Something!

Rev's Forum: Don't Just Sit There, Do Something!

Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

Interesting NKTR Put And Call Options For March 17th

Interesting NKTR Put And Call Options For March 17th

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2017 Options Trading

First Week of NKTR August 2017 Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest Jumps 12.5% For NKTR

Short Interest Jumps 12.5% For NKTR

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

TheStreet Quant Rating: C (Hold)